ATX
Click for more information
1.64% 6.2¢ amplia therapeutics limited

Ann: Update on ACCENT Trial in Pancreatic Cancer, page-10

  1. vrs37
    437 Posts.
    lightbulb Created with Sketch. 211
    clock Created with Sketch.
    27/03/24
    18:08
    Post #: 73089035
    mpact is the name of the p3 trial that showed adding abraxane to gemcitabine increased median survival over gemcitabine by itself. It’s published. Yes abraxane was approved in pancreatic cancer based on mpact.
    ATX Price at posting: 7.7¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 2  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SFX Sheffield Resources achieves milestone production, shipments at Thunderbird, WA
right-arrow Created with Sketch.
TBN Tamboran is developing the NT Beetaloo Basin. To get there, it's listing at $36/sh on the NYSE
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
NIM Nimy extends sulphide targets at Mons with new anomalies identified
right-arrow Created with Sketch.
SXL Southern Cross says no to buy up of Australian Community Media assets
right-arrow Created with Sketch.
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
(20min delay)
Last
6.2¢ 		Change
0.001(1.64%) 		Mkt cap ! $16.84M
Open High Low Value Volume
6.1¢ 6.4¢ 6.1¢ $2.155K 35.07K

Buyers (Bids)

No. Vol. Price($)
1 59863 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 67722 1
View Market Depth
Last trade - 15.45pm 28/06/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.